



## **Kadmon and Chiromics Announce Licensing Agreement for Ground-breaking Chemical Compounds Library**

**NEW YORK, NY and PRINCETON, NJ – January 10, 2012** – [Kadmon Corporation, LLC](#), and Chiromics LLC today announced that they have entered into an agreement under which Chiromics has granted Kadmon a non-exclusive license for use of Chiromics' chemical compound libraries for the discovery and development of pharmaceutical products. Financial terms of the agreement were not disclosed.

The technology used to build Chiromics' libraries, invented by the MacMillan Group at Princeton University, employs a chemical synthesis technique referred to as "cascade catalysis." Cascade catalysis allows for the creation of a diverse collection of molecules that are more complex than, and differentiated from, existing pharmaceutical libraries made using linear drug synthesis, all while retaining drug-like properties, the ability to develop structure–activity relationships and ease of re-synthesis. As a result, where only 15% of proteins have been successfully targeted by existing small molecules, Chiromics' library compounds may reach these and the remaining 85% of targets, many previously thought to be "un-druggable."

"Chiromics' technology and libraries represent a true paradigm shift in pharmaceutical drug discovery," said Samuel D. Waksal, Ph.D., Chairman and Chief Executive Officer of Kadmon. "This platform allows us to identify and produce high-value, pre-clinical candidates against virtually any biologic target with speed and specificity, a feat not possible with other chemistry libraries." Dr. Waksal added, "This agreement is also an example of Kadmon's commitment to accessing and advancing the unsurpassed science and innovation of the academic community here in the United States."

Chiromics' founder David MacMillan, Ph.D., A. Barton Hepburn Professor of Organic Chemistry and Chairman of the Chemistry Department at Princeton University, stated, "Chiromics has developed a technology that can build large, drug-like, broadly diverse collections of molecules with 'accessible complexity,' or novel, three dimensional frameworks which can be readily built using simple catalysis methods. These collections can be made routinely, rapidly and rationally. With its culture of innovation, Kadmon can take full advantage of the potential in this technology by realizing its intended purpose, which is to access the most critical pathways of disease."

### **About Kadmon Corporation**

Kadmon Corporation, LLC is a global company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the

treatment and management of hepatitis C. Kadmon is pioneering medicines in oncology, infectious diseases, immunology and neurodegenerative diseases by using emerging concepts in molecular biology and genomics to develop therapies that target the metabolomic and signaling pathways associated with disease. For more information, visit [www.kadmon.com](http://www.kadmon.com).

### **About Chiromics, LLC**

Chiromics LLC is a drug discovery company that designs and synthesizes broadly diverse chemical compound libraries, using patented organo-catalysis technology, which produces drug-like molecules with stereochemically defined framework. The novel structures and accessible complexity of these compounds expands the potential disease targets and accelerates the hit-to-lead time for identification of novel drugs. Chiromics has established collaborations with biotech and pharmaceutical companies for licensure and screening of these libraries against a broad array of disease targets.

### **Contacts**

For Kadmon Corporation, LLC:

Argot Partners

David Pitts, 212-600-1902

[david@argotpartners.com](mailto:david@argotpartners.com)

For Chiromics LLC:

Debora D. Merrill, MBA, PMP

215-534-1497

[debbie@chiromics.com](mailto:debbie@chiromics.com)